Free Trial
NASDAQ:RGNX

REGENXBIO (RGNX) Stock Price, News & Analysis

REGENXBIO logo
$8.74 +0.31 (+3.68%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$8.74 -0.01 (-0.06%)
As of 07/8/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About REGENXBIO Stock (NASDAQ:RGNX)

Key Stats

Today's Range
$8.43
$8.83
50-Day Range
$7.13
$10.40
52-Week Range
$5.04
$15.36
Volume
620,766 shs
Average Volume
929,570 shs
Market Capitalization
$438.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.63
Consensus Rating
Moderate Buy

Company Overview

REGENXBIO Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

RGNX MarketRank™: 

REGENXBIO scored higher than 90% of companies evaluated by MarketBeat, and ranked 108th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    REGENXBIO has only been the subject of 2 research reports in the past 90 days.

  • Read more about REGENXBIO's stock forecast and price target.
  • Earnings Growth

    Earnings for REGENXBIO are expected to grow in the coming year, from ($4.84) to ($1.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of REGENXBIO is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of REGENXBIO is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    REGENXBIO has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about REGENXBIO's valuation and earnings.
  • Percentage of Shares Shorted

    12.60% of the float of REGENXBIO has been sold short.
  • Short Interest Ratio / Days to Cover

    REGENXBIO has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in REGENXBIO has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    REGENXBIO does not currently pay a dividend.

  • Dividend Growth

    REGENXBIO does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.60% of the float of REGENXBIO has been sold short.
  • Short Interest Ratio / Days to Cover

    REGENXBIO has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in REGENXBIO has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    REGENXBIO has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for REGENXBIO this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,962.00 in company stock.

  • Percentage Held by Insiders

    12.79% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about REGENXBIO's insider trading history.
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

RGNX Stock Analysis - Frequently Asked Questions

REGENXBIO's stock was trading at $7.73 on January 1st, 2025. Since then, RGNX stock has increased by 13.1% and is now trading at $8.74.

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Monday, May, 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by $0.29. The biotechnology company had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative trailing twelve-month return on equity of 53.29% and a negative net margin of 100.62%.
Read the conference call transcript
.

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
5/12/2025
Today
7/09/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RGNX
CIK
1590877
Fax
N/A
Employees
370
Year Founded
N/A

Price Target and Rating

High Price Target
$52.00
Low Price Target
$12.00
Potential Upside/Downside
+261.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$227.10 million
Net Margins
-100.62%
Pretax Margin
-100.62%

Debt

Sales & Book Value

Annual Sales
$83.33 million
Price / Cash Flow
N/A
Book Value
$5.24 per share
Price / Book
1.67

Miscellaneous

Free Float
43,745,000
Market Cap
$438.40 million
Optionable
Optionable
Beta
1.06

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:RGNX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners